Latest from SCCA

Jerald P. Radich, MD, discusses measuring minimal residual disease (MRD) in hematologic malignancies.
Celestia S. Higano, MD, FACP, discusses the state of immunotherapy in prostate cancer.
Elizabeth M. Swisher, MD, discusses the limitations of homologous recombination deficiency as a biomarker of response in ovarian cancer based on findings from the phase III VELIA trial.
This OncLive webinar will uncover the latest treatments in myelofibrosis by Bart Scott, MD. Join us on Tuesday, April 28, 2020 or Thursday, April 30, 2020 at 5 PM or 8 PM EDT.
Petros Grivas, MD, PhD, discusses potential combination regimens with cabazitaxel in prostate cancer.
Jerald P. Radich, MD, discusses the growing importance of MRD assessment in the treatment paradigm for patients with hematologic malignancies.
Elizabeth M. Swisher, MD, discusses how the phase III VELIA/GOG-3005 trial compares with other trials examining up-front maintenance therapy in ovarian cancer.
Veliparib plus chemotherapy extended progression-free survival for BRCA wild-type patients with high-grade serous carcinoma.
Publication Bottom Border
Border Publication